|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
*
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
CA2945335A1
(en)
*
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
WO2015188228A1
(en)
*
|
2014-06-10 |
2015-12-17 |
Monash University |
Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
|
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016069282A1
(en)
*
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
CN107208055B
(zh)
*
|
2015-01-17 |
2021-06-15 |
浙江大学 |
引起免疫原性反应降低的被修饰细胞
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
EP4043556B1
(en)
*
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CA2994746A1
(en)
*
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
US11091780B2
(en)
|
2015-09-18 |
2021-08-17 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
|
CN117070468A
(zh)
|
2015-10-05 |
2023-11-17 |
精密生物科学公司 |
包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
|
|
EP3359660B1
(en)
|
2015-10-05 |
2019-12-04 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
WO2017059557A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Peking University |
Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
EA201891338A1
(ru)
*
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
AU2016369490C1
(en)
*
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
IL297018A
(en)
*
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
|
EP3988655A3
(en)
*
|
2015-12-23 |
2022-08-03 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
KR102438360B1
(ko)
*
|
2016-03-04 |
2022-08-31 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
|
|
US20190328783A1
(en)
|
2016-04-15 |
2019-10-31 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
CN109414512A
(zh)
|
2016-04-22 |
2019-03-01 |
科济生物医药（上海）有限公司 |
用于细胞免疫疗法的组合物和方法
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Ltd |
Protein-based t-cell receptor knockdown
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
CA3041517A1
(en)
|
2016-10-19 |
2018-04-26 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
|
KR102709329B1
(ko)
*
|
2016-10-19 |
2024-09-23 |
셀렉티스 에스.에이. |
개선된 면역 세포들 치료를 위한 타겟인 유전자 삽입
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
EP3529265A2
(en)
*
|
2016-10-19 |
2019-08-28 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
JP7717439B2
(ja)
*
|
2017-01-10 |
2025-08-04 |
ザ ジェネラル ホスピタル コーポレイション |
修飾されたｔ細胞及びその使用方法
|
|
CN107058230B
(zh)
*
|
2017-01-20 |
2020-03-24 |
山东兴瑞生物科技有限公司 |
一种沉默t细胞抗原受体的t淋巴细胞的制备方法
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
EP4414380A3
(en)
|
2017-03-31 |
2024-12-04 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
|
EP4029943A1
(en)
*
|
2017-05-08 |
2022-07-20 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
CN111201438A
(zh)
*
|
2017-06-02 |
2020-05-26 |
朱诺治疗学股份有限公司 |
与和细胞疗法相关的毒性有关的制品和方法
|
|
CA3068604A1
(en)
*
|
2017-06-13 |
2018-12-20 |
Fate Therapeutics, Inc. |
Compositions and methods for inducing myeloid suppressive cells and use thereof
|
|
BR112019026622A2
(pt)
*
|
2017-06-16 |
2020-06-30 |
Sangamo Therapeutics, Inc. |
disrupção direcionada de receptores de célula t e/ou hla
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
WO2019006330A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Indiana University Research And Technology Corporation |
COMPOSITIONS AND METHODS FOR DETECTING REACTIVITY TO ALS
|
|
US12144825B2
(en)
|
2017-06-30 |
2024-11-19 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3068465A1
(en)
|
2017-06-30 |
2019-01-03 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
WO2019011118A1
(zh)
|
2017-07-14 |
2019-01-17 |
苏州克睿基因生物科技有限公司 |
一种基因编辑系统及基因编辑的方法
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CN109468278A
(zh)
*
|
2017-09-08 |
2019-03-15 |
科济生物医药（上海）有限公司 |
基因工程化的t细胞及应用
|
|
BR112020006643A2
(pt)
|
2017-10-03 |
2020-09-24 |
Juno Therapeutics Inc |
moléculas de ligação específica ao hpv
|
|
WO2019071009A2
(en)
*
|
2017-10-05 |
2019-04-11 |
Nantcell, Inc. |
LIPID ANTIGENS AND L-CELL RECEPTORS ON NK CELLS
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
KR20200075851A
(ko)
*
|
2017-10-19 |
2020-06-26 |
셀렉티스 |
개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
|
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技（上海）有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
CN109750035B
(zh)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
|
|
TW201923073A
(zh)
*
|
2017-11-20 |
2019-06-16 |
新加坡商泰莎治療私人有限公司 |
經修飾之k562細胞
|
|
CN112236514A
(zh)
|
2017-12-05 |
2021-01-15 |
塞利亚德股份公司 |
改善细胞过继转移的持久性的组合物和方法
|
|
CN111479917A
(zh)
*
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
|
WO2019118921A1
(en)
|
2017-12-14 |
2019-06-20 |
Flodesign Sonics, Inc. |
Acoustic transducer drive and controller
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US11227325B1
(en)
|
2017-12-18 |
2022-01-18 |
Wells Fargo Bank, N.A. |
Event-based automatic transaction system
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
WO2019154313A1
(zh)
|
2018-02-11 |
2019-08-15 |
江苏恒瑞医药股份有限公司 |
一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
|
|
EP3754018A4
(en)
*
|
2018-02-16 |
2021-11-24 |
Kyoto University |
LOW ANTIGENIC CELL PRODUCTION PROCESS
|
|
CN112534044A
(zh)
*
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
|
KR20210020873A
(ko)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
|
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
AU2019249209A1
(en)
|
2018-04-05 |
2020-10-15 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
CA3095795A1
(en)
|
2018-04-12 |
2019-10-17 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
|
US20190247437A1
(en)
*
|
2018-04-19 |
2019-08-15 |
APDN (B.V.I.), Inc. |
Engineered lymphocyte compositions, methods and systems
|
|
SG11202009626QA
(en)
|
2018-04-20 |
2020-10-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
|
|
SG11202010228RA
(en)
*
|
2018-04-27 |
2020-11-27 |
Crispr Therapeutics Ag |
Methods and compositions of cytotoxic t cell depletion
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12227763B2
(en)
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CA3122131A1
(en)
*
|
2018-09-21 |
2020-03-26 |
Zonghai Li |
Method for gene editing of cell on the basis of crispr/cas system
|
|
CN109266618B
(zh)
*
|
2018-10-18 |
2021-04-23 |
赛元生物科技(杭州)有限公司 |
能够靶向肿瘤细胞的巨噬细胞及其制备方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
CN113015750A
(zh)
*
|
2018-11-07 |
2021-06-22 |
克里斯珀医疗股份公司 |
抗liv1免疫细胞癌症疗法
|
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
US12590148B2
(en)
|
2018-11-26 |
2026-03-31 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
CN111349606A
(zh)
*
|
2018-12-20 |
2020-06-30 |
上海恒润达生生物科技有限公司 |
P60抑制剂与cart细胞联合应用
|
|
EP3908329A4
(en)
|
2019-01-07 |
2022-12-07 |
The Regents of the University of California |
CAGE DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE THERE
|
|
JP7689372B2
(ja)
*
|
2019-01-07 |
2025-06-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
合成分子フィードバック回路及びその使用方法
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
CN109706121A
(zh)
*
|
2019-01-25 |
2019-05-03 |
苏州茂行生物科技有限公司 |
一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
|
|
WO2020168122A1
(en)
*
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
JP7286796B2
(ja)
|
2019-04-03 |
2023-06-05 |
プレシジョン バイオサイエンシズ，インク． |
マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN111826352A
(zh)
*
|
2019-04-22 |
2020-10-27 |
苏州方德门达新药开发有限公司 |
通用型car-t细胞、其制备及应用
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
JP7629414B2
(ja)
*
|
2019-06-04 |
2025-02-13 |
ンカルタ・インコーポレイテッド |
免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
AU2020304139A1
(en)
*
|
2019-06-28 |
2022-02-24 |
Crage Medical Co., Limited |
Cell for resisting transplant reaction and method
|
|
CN120624368A
(zh)
*
|
2019-08-29 |
2025-09-12 |
克莱格医学有限公司 |
抗移植反应的细胞和方法
|
|
KR20220058579A
(ko)
|
2019-09-05 |
2022-05-09 |
크리스퍼 테라퓨틱스 아게 |
보편적 공여자 세포
|
|
US11104918B2
(en)
*
|
2019-09-05 |
2021-08-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
WO2021091935A1
(en)
*
|
2019-11-05 |
2021-05-14 |
Lonza Walkersville, Inc. |
Allogeneic t-cells and methods for production thereof
|
|
AU2020393334A1
(en)
*
|
2019-11-25 |
2022-06-16 |
Kyoto University |
T-cell master cell bank
|
|
AU2020415318A1
(en)
*
|
2019-12-23 |
2022-07-14 |
Cellectis |
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
US20210254005A1
(en)
*
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
|
WO2021202581A1
(en)
*
|
2020-03-30 |
2021-10-07 |
WUGEN, Inc. |
Engineered immune cells for adoptive cell therapy
|
|
JP7821119B2
(ja)
*
|
2020-04-23 |
2026-02-26 |
エーゼットセラピーズ， インコーポレイテッド |
Ｈｌａクラスｉ ｍｈｃの細胞切除
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
WO2021252804A1
(en)
|
2020-06-12 |
2021-12-16 |
Nkarta, Inc. |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
EP4176261A1
(en)
|
2020-07-03 |
2023-05-10 |
Cellectis S.A. |
Method for determining potency of chimeric antigen receptor expressing immune cells
|
|
KR102932097B1
(ko)
*
|
2020-07-06 |
2026-02-27 |
주식회사 지씨셀 |
면역원성이 감소된 신규한 이식용 세포
|
|
WO2022007784A1
(en)
*
|
2020-07-06 |
2022-01-13 |
Nanjing Legend Biotech Co., Ltd. |
Methods of reducing graft rejection of allogeneic cell therapy
|
|
US20230248825A1
(en)
|
2020-07-24 |
2023-08-10 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
JP7766674B2
(ja)
|
2020-07-31 |
2025-11-10 |
セレクティス ソシエテ アノニム |
二重ｃａｒ－ｔ細胞
|
|
AU2021328478A1
(en)
*
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
CN114426583B
(zh)
*
|
2020-10-29 |
2023-10-10 |
中国科学技术大学 |
用于急性髓系白血病的细胞疗法的嵌合抗原受体
|
|
CN114525259B
(zh)
*
|
2020-11-03 |
2025-02-14 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
JP2023552998A
(ja)
*
|
2020-12-03 |
2023-12-20 |
ンカルタ・インコーポレイテッド |
効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
CN114657137A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
KR20230146007A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
WO2022171179A1
(zh)
|
2021-02-10 |
2022-08-18 |
苏州克睿基因生物科技有限公司 |
一种扩增增强子及其应用
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
|
KR20240007179A
(ko)
|
2021-04-30 |
2024-01-16 |
셀렉티스 에스.에이. |
고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포
|
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JP2024519041A
(ja)
|
2021-05-21 |
2024-05-08 |
セレクティス ソシエテ アノニム |
固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強
|
|
EP4347810A4
(en)
*
|
2021-05-24 |
2025-06-04 |
Sangamo Therapeutics, Inc. |
ZINC FINGER NUCLEASES TARGETING CIITA
|
|
US20240365776A1
(en)
|
2021-07-22 |
2024-11-07 |
Iovance Biotherapeutics, Inc |
Method for cryopreservation of solid tumor fragments
|
|
US20240374722A1
(en)
*
|
2021-08-24 |
2024-11-14 |
Cells & Genes Biotech (Shanghai) Co., Ltd |
T cell product and use thereof
|
|
US20230190809A1
(en)
*
|
2021-09-10 |
2023-06-22 |
Tmunity Therapeutics Inc. |
Alternative generation of allogeneic human t cells
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
JP2025504722A
(ja)
*
|
2022-01-25 |
2025-02-18 |
上海邦耀生物科技有限公司 |
修飾細胞及びその使用
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023151620A1
(zh)
*
|
2022-02-09 |
2023-08-17 |
恺兴生命科技(上海)有限公司 |
用于细胞免疫学的组合物和方法
|
|
EP4504221A4
(en)
*
|
2022-03-22 |
2026-02-25 |
Celyntra Therapeutics Sa |
Compositions and methods for generating cells with reduced immunogenicity
|
|
EP4504220A1
(en)
|
2022-04-06 |
2025-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20250325585A1
(en)
*
|
2022-04-15 |
2025-10-23 |
The General Hospital Corporation |
Compositions and methods for reducing cell therapy immunogenicity
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
CN117004604A
(zh)
*
|
2022-04-28 |
2023-11-07 |
南京北恒生物科技有限公司 |
一种ciita基因被敲除的工程化免疫细胞及其用途
|
|
EP4522202A1
(en)
|
2022-05-10 |
2025-03-19 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
EP4282963A1
(en)
|
2022-05-23 |
2023-11-29 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
Nucleic acid modified biological cell with expansion-dependent gene expression
|
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
CN117384852B
(zh)
*
|
2022-07-11 |
2026-01-16 |
士泽生物医药（苏州）有限公司 |
一种表达lgals9的通用型细胞及其制备方法
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024121385A1
(en)
|
2022-12-09 |
2024-06-13 |
Cellectis S.A. |
Two-dose regimen in immunotherapy
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
CN119351338B
(zh)
*
|
2023-09-15 |
2026-01-23 |
士泽生物医药（苏州）有限公司 |
一种表达cd300ld的低免疫原性细胞及其制备方法
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2026002165A1
(zh)
*
|
2024-06-26 |
2026-01-02 |
香港北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|